Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward by Bacon, Siobhan et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of
beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear
factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward
Bacon, Siobhan; Kyithar, Ma; Schmid, Jasmin; Rizvi, Syed R; Bonner, Caroline; Graf, Rolf; Prehn,
Jochen H M; Byrne, Maria M
Abstract: Background Mutations in the transcription factor hepatocyte nuclear factor-1-alpha (HNF1A)
result in the commonest type of maturity onset diabetes of the young (MODY). HNF1A-MODY carriers
have reduced pancreatic beta cell mass, partially due to an increased rate of apoptosis. To date, it has not
been possible to determine when apoptosis is occurring in HNF1A-MODY.We have recently demonstrated
that beta cell apoptosis stimulates the expression of the pancreatic stone protein/regenerating (PSP/reg)
gene in surviving neighbour cells, and that PSP/reg1A protein is subsequently secreted from these cells.
The objective of this study was to determine whether serum levels of PSP/reg1A are elevated during
disease progression in HNF1A-MODY carriers, and whether it may provide information regarding the
onset of beta-cell apoptosis. Methods We analysed serum PSP/reg1A levels and correlated with clinical
and biochemical parameters in subjects with HNF1A-MODY, glucokinase (GCK-MODY), and type 1
diabetes mellitus. A control group of normoglycaemic subjects was also analysed. Results PSP/reg1A
serum levels were significantly elevated in HNF1A-MODY (n = 37) subjects compared to controls (n =
60) (median = 12.50 ng/ml, IQR = 10.61-17.87 ng/ml versus median = 10.72 ng/ml, IQR = 8.94-12.54
ng/ml, p = 0.0008). PSP/reg1A correlated negatively with insulin levels during OGTT, (rho = −0.40, p
= 0.02). Interestingly we noted a significant positive correlation of PSP/reg1A with age of the HNF1A-
MODY carriers (rho = 0.40 p = 0.02) with an age of 25 years separating carriers with low and high
PSP/reg1A levels. Patients with type 1 diabetes mellitus also had elevated serum levels of PSP/reg1A
compared to controls, however this was independent of the duration of diabetes. Conclusion Our data
suggest that beta cell apoptosis contributes increasingly to the pathophysiology of HNF1A-MODY in
patients 25 years and over. PSP/reg1A may be developed as a serum marker to detect increased beta-cell
apoptosis, or its therapeutic response.
DOI: 10.1186/1472-6823-12-13
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-72359
Published Version
 
 
Originally published at:
Bacon, Siobhan; Kyithar, Ma; Schmid, Jasmin; Rizvi, Syed R; Bonner, Caroline; Graf, Rolf; Prehn,
Jochen H M; Byrne, Maria M (2012). Serum levels of pancreatic stone protein (PSP)/reg1A as an
indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha
(HNF1A-MODY) carriers from the third decade of life onward. BMC Endocrine Disorders, 12:13. DOI:
10.1186/1472-6823-12-13
2
RESEARCH ARTICLE Open Access
Serum levels of pancreatic stone protein
(PSP)/reg1A as an indicator of beta-cell apoptosis
suggest an increased apoptosis rate in
hepatocyte nuclear factor 1 alpha (HNF1A-MODY)
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Abstract
Background: Mutations in the transcription factor hepatocyte nuclear factor-1-alpha (HNF1A) result in the
commonest type of maturity onset diabetes of the young (MODY). HNF1A-MODY carriers have reduced pancreatic
beta cell mass, partially due to an increased rate of apoptosis. To date, it has not been possible to determine when
apoptosis is occurring in HNF1A-MODY.We have recently demonstrated that beta cell apoptosis stimulates the
expression of the pancreatic stone protein/regenerating (PSP/reg) gene in surviving neighbour cells, and that
PSP/reg1A protein is subsequently secreted from these cells. The objective of this study was to determine whether
serum levels of PSP/reg1A are elevated during disease progression in HNF1A-MODY carriers, and whether it may
provide information regarding the onset of beta-cell apoptosis.
Methods: We analysed serum PSP/reg1A levels and correlated with clinical and biochemical parameters in subjects
with HNF1A-MODY, glucokinase (GCK-MODY), and type 1 diabetes mellitus. A control group of normoglycaemic
subjects was also analysed.
Results: PSP/reg1A serum levels were significantly elevated in HNF1A-MODY (n = 37) subjects compared to controls
(n = 60) (median = 12.50 ng/ml, IQR = 10.61-17.87 ng/ml versus median = 10.72 ng/ml, IQR = 8.94-12.54 ng/ml,
p = 0.0008). PSP/reg1A correlated negatively with insulin levels during OGTT, (rho =−0.40, p = 0.02). Interestingly we
noted a significant positive correlation of PSP/reg1A with age of the HNF1A-MODY carriers (rho = 0.40 p = 0.02) with
an age of 25 years separating carriers with low and high PSP/reg1A levels. Patients with type 1 diabetes mellitus
also had elevated serum levels of PSP/reg1A compared to controls, however this was independent of the duration
of diabetes.
Conclusion: Our data suggest that beta cell apoptosis contributes increasingly to the pathophysiology of
HNF1A-MODY in patients 25 years and over. PSP/reg1A may be developed as a serum marker to detect increased
beta-cell apoptosis, or its therapeutic response.
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Background
Maturity-onset diabetes of the young (MODY), is a
monogenic form of diabetes characterized by autosomal
dominant mode of inheritance including a three-
generation family history of diabetes, age at diagnosis of
diabetes of 25 years or less in at least one family member
and reduced glucose-stimulated insulin secretion [1].
MODY can result from mutations in at least six different
genes [2]. The two most common forms are HNF1A-
MODY and glucokinase (GCK)-MODY in all populations
studied accounting for approximately 70% of all cases
[3].
Insulin secretory defects have been observed in car-
riers of HNF1A-MODY and GCK-MODY with and
without diabetes [4,5]. HNF1A encodes a transcription
factor important for pancreatic development, beta cell
differentiation and function. HNF1A-MODY subjects
with pre-diabetes have defective glucose-induced beta
cell insulin secretion indicative of reduced beta cell mass
[4]. Homozygous hnf-1a/tcf-1 knockout mice likewise
have a reduced beta cell mass [6]. HNF1A-MODY is
associated with a severe and progressive clinical course
with up to 50% of patients requiring insulin. The decline
in functional beta cell mass may be attributed to
increased beta cell apoptosis [7-9]. Mutations in HNF1A
are usually detected later in life when they are inciden-
tally discovered through a screening programme or if
subjects become symptomatic. Diabetes usually becomes
manifest when additional superimposed environmental
factors supervene such as a physiological decrease in in-
sulin sensitivity with puberty and pregnancy. The decline
in beta cell mass therefore, is progressive but gradual.
The possible contribution of apoptosis to this decrease
in beta cell mass however, has not been investigated due
to a lack of accessible, specific biomarkers for beta cell
apoptosis.
In contrast to HNF1A-MODY carriers, patients with
GCK-MODY do not show a comparably progressive de-
crease in beta cell mass. Glucokinase is a key regulatory
enzyme in the pancreatic beta cell catalyzing the conver-
sion of glucose to glucose-6-phosphate, the first step in
glycogen storage and glycolysis. GCK-MODY is often
subclinical but can be detected at any stage of life
[10,11]. GCK-MODY carriers have mild fasting and
post-prandial hyperglycaemia from birth, lack of pro-
gression, and absence of insulin requirement and vascu-
lar complications [10-12]. Patients with GCK mutations,
in contrast to HNF1A-MODY rarely require any
pharmacological intervention and the majority are man-
aged with diet alone.
One of the challenges in evaluating the contribution of
beta cell apoptosis in human disease development is the
lack of appropriate tools to evaluate the extent of beta
cell apoptosis in patients other than post mortem studies
[13]. Another complicating factor is that the actual
process of apoptosis execution is very rapid and occurs
within minutes [14], and apoptosing cells can rapidly de-
tach from the extracellular matrix, and are subsequently
phagocytised [15], thereby limiting the chance of detect-
ing apoptosis by in-vivo imaging techniques. An alterna-
tive strategy therefore, is to detect signals that are
generated directly or indirectly from apoptosing beta
cells. Previous studies from our laboratory have demon-
strated that beta cells undergoing apoptosis induce the
expression of the PSP/reg gene in neighbouring beta
cells. This paracrine gene induction occurs in a caspase-
dependent manner, and is mediated by the shedding of
microparticles from apoptosing cells. PSP/reg1A protein
is subsequently secreted from neighbouring cells, and
provides a regenerative cue to the microenvironment.
We also demonstrated elevated serum levels of PSP/
reg1A, the human homologue of PSP/reg, in human
subjects with HNF1A-MODY and in subjects with type
1 diabetes mellitus, suggesting that the endocrine pan-
creas is the primary source of this signal [16].
In the present study, we sought to clinically validate
this finding with a larger group and to investigate
whether elevated PSP/reg1A levels in HNF1A-MODY
correlated with a clinical phenotype and progression of
disease. We also investigated whether PSP/reg1A was
upregulated in GCK-MODY.
Methods
Subjects
37 HNF1A-MODY and 13 patients with GCK-MODY
participated in the study. The HNF1A-MODY group
consisted of 13 different families and the GCK-MODY
group represented 6 different families. HNF1A muta-
tions included L17H, G207D, P291finsC, S352fsdelG,
F426X, P379T, and IVS7-6 G>A, and R200Q/N. GCK
mutations included D160N, Y61X, A378V, L146fs,
Ile293Arg, and p.Asp311fs. A historic value for PSP/
reg1A was also available based on data from 60 normo-
glycaemic subjects (median = 10.72 ng/ml, IQR= 8.94-
12.54 ng/ml). In addition, 27 patients with antibody
positive (GAD and or Islet cell antibody) type 1 diabetes
mellitus were recruited from the diabetes outpatients in
the Mater Misericordiae University Hospital. Clinically,
on presentation, all subjects with type 1 diabetes mellitus
had osmotic symptoms with ketosis requiring insulin
from diagnosis. There was no significant family history
recorded in any of the subjects with type 1 diabetes mel-
litus. All subjects were BMI-matched. The clinical char-
acteristics of all groups analyzed are presented in
Table 1 and Table 2 contains the glucose levels during
OGTT in HNF1A-MODY subjects. Ethics approval was
attained from the ethics committee at the Mater
Bacon et al. BMC Endocrine Disorders 2012, 12:13 Page 2 of 8
http://www.biomedcentral.com/1472-6823/12/13
Misericordiae University Hospital. All study subjects
gave written informed consent to participate in the
study.
Clinical and laboratory measurements
All subjects underwent a full clinical assessment, includ-
ing a full medical history and physical examination. An-
thropometric measurements including weight, height,
and body mass index (BMI) were obtained. Blood sam-
ples were drawn for the measurement of HBA1c, fasting
lipids, full blood count, thyroid function, renal and liver
profiles, glutamic acid decarboxylase (GAD65) auto anti-
bodies, and pancreatic islet cell auto antibodies (ICA). In
addition a blood sample for PSP/reg1A was drawn.
A 75 g OGTT was performed on subjects (excluding
subjects with type 1 diabetes mellitus) after a 12-h over-
night fast with measurement of glucose, insulin and C-
peptide at baseline and at 30 minute intervals for 120
minutes to determine the degree of glucose tolerance
and insulin secretory response. In patients with diabetes,
oral hypoglycaemic agents were stopped at least 48 h
before the OGTT while, in those taking insulin, long-
acting insulin therapy was stopped for 24-h and short-
acting insulin stopped for 12-h prior to OGTT. The
diagnostic criteria for the American Diabetes Associ-
ation was used to define the degree of glucose tolerance.
Assays
All laboratory analyses were performed with commer-
cially available standardized methods. The plasma
glucose concentration was measured using Beckman
Synchron DXC800 (Beckman Instruments Inc, Brea,
USA). HbA1c was determined using high performance li-
quid chromatography (Menarini HA81-10, Rome, Italy).
Insulin and C-peptide were analyzed using Immulite
2000 immunoassay (Siemens Healthcare Diagnostics,
Deerfield, IL, USA). GAD antibodies were analysed using
competitive fluid-phase radioimmunoassay by the neu-
rosciences group in John Radcliffe Hospital in Oxford,
and ICA by indirect immunofluoresence test by the
Supra-Regional Protein Reference Unit and Department
of Immunology in Sheffield, UK.
The ELISA to quantify human PSP/reg was performed
using the anti-sera from rabbits and guinea pigs immu-
nized with recombinant human PSP/reg protein as pre-
viously described [17,18]. Patient serum PSP/reg levels
were compared with standard amounts of protein of re-
combinant human PSP/reg. The technical specificity of
the PSP/reg assay has been determined: addition of
0.5 ng/ml to diluted serum from different individuals
gave a recovery of 101 +/− 20% (n = 19). The intra-plate
and inter-plate variability is less than 5% and 10%
respectively.
Statistical analysis
Data are presented as median and interquartile range
(IQR). Areas under the curve (AUCs) for insulin were
calculated using the trapezoidal rule. Statistical analysis
was performed using MATLAB (Mathworks, Natick,
Massachusetts, USA). Differences between groups were
determined by two-sided Mann–Whitney/Wilcoxon
rank sum test. The Spearman correlation test was used
for correlation analysis. Differences and correlations
were considered to be significant at P< 0.05.
Results
PSP/reg1A serum levels are elevated in HNF1A-MODY
subjects and correlate negatively with AUC insulin
We determined the fasting serum PSP/reg1A levels in
the HNF1A-MODY group using a previously described
ELISA assay [17,18]. The levels of PSP/reg1A were
Table 1 Clinical characteristics of subjects
Subject group HNF1A-MODY Glucokinase Mutations Type 1 diabetes mellitus
Number of subjects 37 13 27
Age (yrs) 43 (21–52) 38 (27–60) 41 (23–52)
Diabetes duration (yrs) 6 (3–19) From birth 21 (3–34)
BMI (kg/m2) 24.4 (22.0-26.3) 24.0 (21.6-26.4) 24.4 (22.3-28.6)
Fasting plasma glucose (mmol/l) 6.8 (5.4-9.0) 6.5 (6.0-7.0) 9.6 (8.5-11.1)
Fasting C peptide (ng/ml) 1.5 (1.0-1.8) 1.3 (1.0-1.7) <0.5a
HbA1c (%) 7.0 (6.3-7.9) 6.3 (6.1-6.6) 7.7 (7.2-9.2)
Clinical characteristics of subjects with HNF1A-MODY, GCK-MODY, type 1 diabetes mellitus,
a =median is below detection limit. Data are given as median (IQR).
Table 2 Glucose levels during OGTT in HNF1A-MODY
subjects
Time (mins) Glucose (mmol/l)
0 7.6 ± 0.5
30 13.3 ± 0.9
60 17.7 ± 1.5
90 18.3 ± 1.5
120 18.6 ± 1.9
Data are presented as mean and standard error of the mean (SEM).
Bacon et al. BMC Endocrine Disorders 2012, 12:13 Page 3 of 8
http://www.biomedcentral.com/1472-6823/12/13
significantly elevated in subjects with HNF1A-MODY
compared to historic controls (median = 12.5 ng/ml,
IQR= 10.61-17.87 ng/ml versus median = 10.72 ng/ml,
IQR= 8.94-12.54 ng/ml, p = 0.0008, Figure 1). These
results validate our previous finding that PSP/reg1A,
produced in response to beta cell apoptosis, is elevated
in HNF1A-MODY [16].
We next sought to ascertain the presence or absence
of a correlation between levels of PSP/reg1A and insulin
levels determined using a 120 minute OGTT and calcu-
lated AUC insulin using trapezoidal rule in subjects with
HNF1A-MODY. We found a negative correlation be-
tween AUC insulin and PSP/reg1A (rho =−0.40, p = 0.02,
Figure 2A).
PSP/reg1A levels do not correlate with HbA1c, triglyceride
levels or clinical infectious/inflammatory markers
Potential factors leading to beta cell death in diabetes in-
clude high concentrations of glucose [19]. Surprisingly,
however, we did not find a correlation between PSP/
reg1A and HbA1c (rho =−0.09, p = 0.62, Figure 2B).
There was, likewise no correlation noted with total chol-
esterol (rho = 0.11, p = 0.58), HDL cholesterol (rho = 0.12,
p = 0.54), LDL cholesterol (rho = 0.05, p = 0.78) or trigly-
cerides (rho =−0.21, p = 0.25). It has also been postulated
that PSP may be increased during infection/inflamma-
tion [20]. However, we did not detect any correlation
with common markers of inflammation such as total
white cell count (rho = 0.30, p = 0.09) or neutrophil
count (rho = 0.30, p = 0.09).
PSP/reg1A serum level increase with age in HNF1A-MODY
subjects
As beta cell dysfunction progresses in HNF1A-MODY
patients [21], we next explored whether there was a cor-
relation between PSP/reg1A serum levels and age. We
found a positive correlation between age and PSP/reg1A
(r = 0.40, p = 0.02). Further analysis of the data demon-
strated that those diagnosed with HNF1A-MODY under
25 years of age had significantly lower levels of PSP/
reg1A than those diagnosed at the age of 25 years or
over (median = 10.85 ng/ml, IQR = 9.41-12.12 ng/ml ver-
sus median = 15.40 ng/ml, IQR = 11.05-19.91 ng/ml,
p = 0.0039, Figure 3).
PSP/reg1A serum levels are elevated in autoantibody-
type 1 diabetes mellitus, but independent of age and
disease onset
We next wished to confirm these data in a second group
of patients with the principal pathogenic factor being beta
cell destruction. A cohort of auto-antibody positive, BMI-
matched type 1 diabetes mellitus patients were compared
with the (n= 60) historic controls. We found that
PSP/reg1A levels were significantly higher in the type
1 diabetes mellitus population (median= 13.52 ng/ml,
IQR=10.91-19.01 ng/ml versus median= 10.72 ng/ml,
IQR=8.94-12.54 ng/ml, p = 0.0007, Figure 1). Interest-
ingly, we did not detect any correlation between age (rho=
0.27, p = 0.18) or disease onset (rho= 0.33, p = 0.09) and
PSP/reg1A serum levels in this cohort of patients, suggest-
ing that beta cell apoptosis occurs during disease inde-
pendent of these factors. As with the subjects with
HNF1A-MODY there was no correlation between PSP/
reg1A levels and HbA1c (rho=−0.08, p = 0.68). There was
likewise, no correlation with total cholesterol (rho=−0.08,
p = 0.75), HDL cholesterol (rho= 0.24, p = 0.32), LDL chol-
esterol (rho=−0.31, p = 0.19), triglycerides (rho=−0.07,
p = 0.77), or white cell count (rho=−0.22, p = 0.39).
PSP/reg1A serum levels are not significantly elevated in
GCK-MODY
We next tested whether patients with GCK-MODY also
showed a pronounced increase in PSP/reg1A levels. Al-
though there was a tendency towards elevated PSP/
reg1A levels, we did not find a statistically significant
GCK-MODYHNF1A-MODY T1DMControl0
5
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20
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35
40
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(ng
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*
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Figure 1 Serum levels of PSP/reg1A in HNF1A-MODY(Δ), T1DM
(○) and GCK-MODY (♦) versus non-diabetic controls (▲). Solid
lines/box plot showing median and interquartile range (IQR) and
dotted line showing mean. Serum levels of PSP/reg1A in HNF1A-
MODY are at a median of 12.50 ng/ml showing an IQR of 10.61 to
17.87 ng/ml in n = 37 patients. The median in n = 27 type 1 diabetes
mellitus (T1DM) patients is 13.52 ng/ml with IQR of 10.91 to
19.01 ng/ml and the median in n = 60 control subjects is
10.72 ng/ml and IQR is 8.94-12.54 ng/ml. A Mann–Whitney U-test of
the groups resulted in (*) p = 0.0008 for differences between
HNF1A-MODY and controls and (*) p = 0.0007 for comparison of
T1DM versus controls. The median of GCK-MODY is 12.27 ng/ml
with an IQR of 9.79 to 16.47 ng/ml in n = 13 patients, which resulted
in (n.s.) p = 0.164 when compared to controls.
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elevation of PSP/reg1A level when compared to historic
controls (median = 12.27 ng/ml, IQR = 9.79-16.47 ng/ml
versus median = 10.72 ng/ml, IQR= 8.94-12.54 ng/ml,
p = 0.16, Figure 1). There was also no correlation noted
with AUC insulin (r = 0.21, p = 0.55) or HbA1c (r = 0.52,
p = 0.07). There was no statistically significant difference
between serum PSP/reg1A levels of GCK-MODY and
HNF1A-MODY or type 1 diabetes mellitus patients
(p = 0.55/p = 0.34 respectively).
Discussion
The Irish HNF1A-MODY cohort investigated in this
study has been recently characterized [22]. This study
reported on a mutation identification rate of 30.5%
among Irish adults clinically selected for HNF1A-MODY
from attendees at the diabetes clinic. In the present
study, we report that PSP/reg1A levels are significantly
elevated in human subjects with HNF1A-MODY when
compared to controls. Higher levels of circulating PSP/
reg1A in HNF1A-MODY were associated with increased
age suggesting that the rate of beta cell apoptosis
increases during disease progression and within the third
life decade. PSP/reg1A did not correlate with HbA1c nor
did it correlate with the common clinical infectious/in-
flammatory markers. Patients with type 1 diabetes melli-
tus also showed elevated PSP/reg1A levels independent
of age or disease onset. Together these data suggest that
PSP/reg1A may be a clinical indicator of beta cell
apoptosis.
We have previously provided biological evidence in
insulinoma cell lines and transgenic mice models of
HNF1A-MODY, that beta cells undergoing apoptosis in-
duce the expression of the PSP/reg gene in neighbouring
beta cells [16]. The induction of PSP/reg during apop-
tosis was inhibited in cells treated with caspase inhibi-
tors. Paraffin embedded pancreatic sections from
5 month old diabetic mice expressing HNF1A-MODY in
beta cells also demonstrated elevated expression of PSP/
reg throughout the islets compared with wild-type mice,
with PSP/reg positive cells positioned in the vicinity of
cells displaying apoptotic nuclear morphology. These
earlier findings demonstrated that PSP/reg1A gene ex-
pression was induced during apoptosis in in vitro and
animal models of diabetes. One of the core findings of
the present study is that PSP/reg1A serum levels may be
used as a non-invasive marker to evaluate the extent of
0 50 100 150 200 250
AUC insulin
0
5
10
15
20
25
30
35
40
PS
P 
(ng
/m
l)
0 5 10 15
HbA1c (%)
0
5
10
15
20
25
30
35
40
PS
P 
(ng
/m
l)
A B
Figure 2 Correlations of PSP/reg1A in HNF1A-MODY. (A) PSP/reg1A correlation with AUC of insulin (Spearman r =−0.40, p = 0.02, n = 34). The
regression curve highlights the negative correlation (R2 = 0.17). (B) No correlation was found between PSP/reg1A and HbA1c (Spearman r =−0.09,
p = 0.62, n = 37).
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Figure 3 Serum levels of PSP/reg1A at age< 25 years (Δ)
versus older (▲) in HNF1A-MODY subjects. Solid lines/box plot
showing median and interquartile range and dotted line showing
mean. The medians of PSP/reg1A are demonstrated between young
HNF1A-MODY (median= 10.85 ng/ml, IQR = 9.41-12.12 ng/ml, n = 12)
and older subjects (median= 15.40 ng/ml, IQR = 11.05-19.91 ng/ml,
n = 25), Mann–Whitney U-test (*) p = 0.004.
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beta cell apoptosis during disease progression in human
subjects.
The development and implementation of non-invasive
techniques for the quantitative measurement of beta cell
apoptosis would help in the early diagnosis of beta cell
dysfunction in pre-clinical phases of diabetes. Further-
more, it would enable evaluation of emerging thera-
peutic approaches which focus on preservation of beta
cell mass through stimulation of anti-apoptotic signal-
ling. Currently, only indirect methods that evaluate total
beta cell mass through secretory responses of islet cells
are available, such as arginine-induced insulin secretion
[23,24]. These rely on measuring insulin secretion fol-
lowing different metabolic stimuli. Direct visualization of
either native or transplanted pancreatic islets was unsuc-
cessful due to their small size, the little difference in
physical characteristics from the surrounding tissue, and
their relatively low number dispersed over a large area of
the pancreas or the liver as the most common site of
transplantation [25]. However, modern diagnostic equip-
ment may provide very high sensitivity by positron emis-
sion tomography (PET) and single photon emission
computed tomography (SPECT), spatial resolution by
magnetic resonance imaging (MRI), or both (by PET/
CT) [26]. Despite these advances in imaging devices, the
main problem is the lack of a specific structural or mo-
lecular marker to enable differentiation between scat-
tered islets or single beta cells, and surrounding tissue.
Moreover, these techniques require dedicated imaging
centres and are costly.
A previously reported paper hypothesized as to
whether serum reg protein levels could be representative
of the regenerative process at the beta cell level during
the early phases of type 1 diabetes mellitus in humans
[27]. We have found that PSP/reg1A levels are higher in
type 1 diabetes mellitus but independent of disease onset
or age. This finding should be considered in the context
of recent investigations suggesting that beta cell regener-
ation may occur even in patients with long standing type
1 diabetes mellitus [28-31]. Our study indicates that this
regeneration may be accompanied by continuing beta
cell apoptosis, even in patients with long standing type 1
diabetes mellitus. Therefore, therapeutic interventions
that boost beta cell survival could be a valuable thera-
peutic approach even in long standing type 1 diabetes
mellitus.
In contrast to type 1 diabetes mellitus patients who
have a rapid disease onset, HNF1A-MODY carriers rep-
resent an interesting and important study group for the
study of beta cell apoptosis during disease progression
as carriers will ultimately develop diabetes [1]. As
demonstrated in HNF1A-MODY subjects’ beta cell
apoptosis appeared to correlate with age, but not with
HbA1c suggesting that aging is an important risk factor,
and that young islets have an increased resistance to-
wards mutant HNF1A-induced apoptosis. Although
patients with a GCK-MODY mutation did not have sig-
nificantly elevated levels of serum PSP/reg1A when
compared to controls, we cannot draw any conclusions
in relation to this group due to the limited numbers
available. There was also no statistically significant dif-
ference between serum PSP/reg1A levels of GCK-
MODY and HNF1A-MODY or type 1 diabetes mellitus
patients.
The pancreatic acinar cells are considered to be the
most important source of PSP/reg under normal condi-
tions however in pathological conditions other cells/tis-
sues may contribute to elevated levels of the protein.
PSP has been shown to be elevated in liver/pancreatic
disease and in chronic renal failure [32]. When originally
discovered, PSP/reg was proposed to be a marker of
pancreatic injury in pancreatitis [33,34] however; subse-
quent studies have failed to demonstrate elevated levels
even after severe pancreatitis [35]. In this study the sub-
jects had normal liver and renal function. Furthermore,
PSP/reg1A levels did not correlate with infection/inflam-
mation markers such as white cell count.
As a result of the growing interest in beta cell preser-
vation as a potential cure for diabetes, a number of dif-
ferent treatments aimed at protecting the beta cell and
maintaining beta cell mass have been evaluated. Insuli-
notropic agents such as repaglinide or GLP-1 have been
shown to be cytoprotective in-vitro and in animal mod-
els of diabetes [36,37]. From a clinical aspect, beta cell
protection may also be induced by reducing the periph-
eral insulin demand by either improving sensitivity e.g.
through physical exercise, pharmacologically using met-
formin/glitazones, or by lowering blood glucose through
the administration of exogenous insulin [38-40]. Our
study suggests that PSP/reg1A serum levels may be use-
ful as a biomarker for such potentially cytoprotective
treatment paradigms.
Conclusion
PSP/reg1A may be developed as a serum marker to de-
tect alterations in the rate of beta cell apoptosis during
disease or in response to treatment. Furthermore, our
data suggests that beta cell apoptosis contributes to the
pathophysiology of HNF1A-MODY in patients 25 years
and over.
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